secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rallybio Corp (RLYB)
CIK:        0001739410
Form:       8-K
Filed at:   2026-06-01T12:07:23+00:00
Accession:  0001193125-26-249790
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 1.01, 3.02, 5.01, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rallybio to merge with Avenzo Therapeutics; pre-merger Avenzo holders to own ~56.6% of combined co
--------------------------------------------------------------------------------

- Avenzo stockholders expected to own ~56.6% of combined co; Rallybio stockholders ~2.8%; new investors in $215M concurrent financing ~40.6% on fully diluted basis.
- Rallybio will distribute net cash to stockholders pre-closing; holders receive CVRs for potential proceeds from legacy asset sales.
- Combined company led by Avenzo management: Dr. Athena Countouriotis as CEO, Scott Lipman as CFO; current Rallybio executives/directors expected to resign.
- Merger requires Rallybio stockholder approval, reverse stock split, name change to Avenzo Therapeutics; closing conditions include $215M financing and no material adverse effect.
- Support agreements from ~24.3% of Rallybio stockholders and ~78% of Avenzo stockholders; lock-up agreements for Avenzo insiders for 180 days post-closing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739410/000119312526249790/0001193125-26-249790-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739410/000119312526249790/d19106d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-249790

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer